Celldex Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Celldex Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Celldex Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Celldex Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Celldex Therapeutics Inc (Celldex) is a biopharmaceutical company that focuses on advancing mast cell biology and developing therapeutic antibodies. The company researches and develops monoclonal and bispecific antibodies to address mast cell-mediated diseases. Its major products include Barzolvolimab, a monoclonal antibody targeting the KIT receptor, and CDX-622 is a bispecific antibody that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin (TSLP) and depleting mast cells via stem cell factor (SCF) starvation. The company offers its products for patients with severe inflammatory, allergic, autoimmune, and other diseases with limited treatment options. The company's products are utilized in various therapeutic areas, including dermatologic, respiratory, gastrointestinal, and allergic conditions. Celldex is headquartered in Hampton, New Jersey, the US.
Headquarters
United States of America
Address
Suite 220, 53 Frontage Road, Hampton, New Jersey, 08827
Website
www.celldex.com
Telephone
1 908 4547120
No of Employees
198
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CLDX (NASD)
Revenue (2024)
$1.5M
-78%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-63.9%
(2024 vs 2023)
Market Cap*
$3.3B
Net Profit Margin (2024)
XYZ
-644.8%
(2024 vs 2023)
* As of and is in US$
Celldex Therapeutics Inc premium industry data and analytics
Products and Services
| Products |
|---|
| - |
| Pipeline: |
| Barzolvolimab (CDX-0159): Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Prurigo Nodularis, Eosinophilic Esophagitis and Atopic Dermatitis |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Celldex Therapeutics Inc | Eli Lilly and Co | Pfizer Inc | AbbVie Inc | Novartis AG |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | Switzerland |
| City | Hampton | Indianapolis | New York City | North Chicago | Basel |
| State/Province | New Jersey | Indiana | New York | Illinois | Basel-Stadt |
| No. of Employees | 198 | 50,605 | 75,000 | 57,000 | 75,267 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Anthony S. Marucci | President; Chief Executive Officer; Director | Executive Board | 2008 | 64 |
| Sam Martin | Senior Vice President; Chief Financial Officer | Senior Management | 2017 | 55 |
| Diane C. Young, M.D. | Chief Medical Officer; Senior Vice President | Senior Management | 2019 | 70 |
| Tibor Keler, Ph.D. | Chief Scientific Officer; Executive Vice President | Senior Management | 2014 | 67 |
| Ronald A. Pepin, Ph.D. | Chief Business Officer; Senior Vice President | Senior Management | 2011 | 70 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer